The biotechnology industry is still a growth industry. Investing in an ETF gives me exposure to an industry I don't fully understand. The two major ETFs in the industry have different portfolio ...

In the world of biotechnology investing, companies often struggle to bring new drugs to market. Developing treatments for rare diseases can be incredibly expensive, and because these conditions affect ...

The biotech sector, tracked by iShares Biotechnology ETF, rallied 40% in six months on rising M&A activity, still below four-year levels. Read why IBB ETF is a hold.

After being mostly down over the past three years, the biotech sector rallied hard to end 2023. The SPDR S&P Biotech ETF (NYSEARCA:XBI) is up 31% in the last three months. From 2010 through 2019, ...

For biotech firms, a bit of positive news—a key result from clinical trials or new drug discovery, say—can be the difference between a major rally based on a path toward sustained profitability and a ...

Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, EBITDA Accretion and Cashflow Generation ...

For decades, the hope of local bioscience industry leaders and elected officials has been that Los Angeles County would develop into a major bioscience cluster capable of attracting the billions of ...

Two new reports paint the most detailed portraits yet of the increasing globalization of the biotech industry and the growing competition between U.S. metropolitan areas to become centers of ...

BRUSSELS, May 15, 2025 /PRNewswire/ -- Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international exhibitions ...